Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer
OwnerPablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalezinventors
Life of this patent
Estimating the term…
Abstract
The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
Claims21
A compound for treating cancer cells in a mammal, wherein said compound is a nanoliposomal formulation comprising c-MYC-siRNA, a phospholipid compound, a lipid and a PEG-phospholipid.
A compound for treating cancer cells in a mammal, wherein said compound is a nanoliposomal formulation comprising c-MYC-siRNA, a polyether compound, a detergent and a phospholipid.
A method for treating ovarian cancer in a mammal comprising administering to said mammal, a therapeutically effective amount of an nanoliposomal formulation comprising c-MYC-siRNA, a phospholipid compound, a lipid and a PEG-phospholipid.
A method for cell growth arrest in ovarian cancer cell comprising administering to a mammal, a therapeutically effective amount of a nanoliposomal formulation comprising c-MYC-siRNA, a phospholipidcompound, a lipid and a PEG-phospholipid.
A method for treating ovarian cancer cells resistant to chemotherapy drugs in a mammal comprising administering to said mammal a first chemotherapy drug and a therapeutically effective amount of a nanoliposomal formulation comprising c-MYC-siRNA, a phospholipidcompound, a lipid and a PEG-phospholipid.
A method for producing a nanoliposomal formulation comprising c-MYC-siRNA, a phospholipids compound, a solvent, a lipid and a PEG-phospholipid.
Dependencies are inferred from the claim text.